Related Experiment Video
Updated: Aug 15, 2026

Denver Papillae Protocol for Objective Analysis of Fungiform Papillae
Published on: June 8, 2015
Comparative testing of the potency of different PPD preparations
Abstract:
The potency of different PPD preparations, obtained from M. tuberculosis and M. bovis was investigated in the guinea-pig test. The groups of animals were immunized with dried mycobacterium powder (obtained from M. tuberculosis, M. bovis and M. tuberculosis + M. bovis), suspended in sterile liquid paraffin oil and with BCG vaccine. The potency tests were carried out according to the WHO requirements. Independently of the immunization method, a significantly greater potency of homologous versus heterologous PPD could not be demonstrated. The mixed PPD preparation (obtained from M. tuberculosis + M. bovis) was fractionated on SEPHAROSE 6 B and SEPHACRYL S 200 column. The potency of different fractions compared to the non-fractionated material was determined in the guinea-pig tests. The animals were immunized by dried mycobacterium powder (obtained from M. tuberculosis + M. bovis), suspended in sterile liquid paraffin oil. The IU content of fractions was calculated according to their protein N content, compared to the non-fractionated material. In these experimental conditions PPD fractions with significantly greater potency than the non-fractionated material could not be found. As a final conclusion we suggest that the desired improvement of tuberculosis diagnostics can be achieved not only by using PPDs derived from different mycobacteria but by further immunochemical purification of the tuberculin preparations and extensive testing of the purified materials in human beings as well.
Insights
Tuberculin Purified Protein Derivative (PPD) potency from M. tuberculosis and M. bovis was tested. Fractionation and purification did not yield PPD with significantly greater potency for improved tuberculosis diagnostics.
Area of Science:
- Immunology
- Microbiology
- Tuberculosis Diagnostics
Background:
- Tuberculosis remains a global health challenge, necessitating improved diagnostic tools.
- Purified Protein Derivative (PPD) is a key component in tuberculin skin tests for diagnosing tuberculosis.
- Evaluating PPD potency from different Mycobacterium species is crucial for diagnostic accuracy.
Purpose of the Study:
- To investigate the potency of PPD preparations from M. tuberculosis and M. bovis.
- To assess the efficacy of fractionating and purifying PPD for enhanced diagnostic potential.
- To determine if PPD from different mycobacteria or purified fractions offer superior potency.
Main Methods:
- Guinea-pig tests were employed to evaluate PPD potency.
- Animals were immunized with mycobacterium powder (M. tuberculosis, M. bovis, or combined) in liquid paraffin oil, and with BCG vaccine.
- Mixed PPD was fractionated using SEPHAROSE 6 B and SEPHACRYL S 200 columns, with potency assessed via guinea-pig tests and protein N content.
Main Results:
- No significant difference in potency was observed between homologous and heterologous PPD, irrespective of the immunization method.
- Fractionation of mixed PPD did not yield fractions with significantly greater potency compared to the non-fractionated material.
- Calculated International Units (IU) based on protein N content did not reveal enhanced potency in fractions.
Conclusions:
- Current PPD preparations from M. tuberculosis and M. bovis, even when fractionated, do not demonstrate significantly enhanced potency in guinea-pig models.
- Improving tuberculosis diagnostics may require further immunochemical purification of tuberculin preparations.
- Extensive testing of purified tuberculin materials in human subjects is recommended for future diagnostic advancements.
More Related Videos
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
04:50Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
Published on: August 4, 2023